Status:
UNKNOWN
Effects of Esketamine on Postpartum Depression
Lead Sponsor:
Qinghai University
Collaborating Sponsors:
Qinghai Red Cross Hospital
Conditions:
Postpartum Depression
Eligibility:
FEMALE
25-35 years
Phase:
PHASE4
Brief Summary
Different concentrations of Esketamine were used after cesarean section. Through the evaluation of postoperative psychological status and analgesic effect, the optimal dosage of Esketamine to exert th...
Detailed Description
A total of 500 cases of pregnant women undergoing cesarean section under spinal anesthesia in Qinghai Red Cross Hospital from February 2022 to September 2022 were selected. General information of the ...
Eligibility Criteria
Inclusion
- All participating patients signed an informed consent form;
- Age 25-35 years old;
- BMI≤35kg/m2;
- ASA classification I or II;
- Ultrasound showed a single pregnancy in the uterus Fetus, placental maturity grade Ⅱ+
Exclusion
- Unable or unwilling to sign the consent form, or unable to follow the research procedures;
- History of thyroid disease;
- A history of local anesthetic allergy;
- A history of addiction or abuse to opioids and ketamine;
- Preoperative mental illness; severe eclampsia;
- Abnormal ECG, hypertension and severe heart Medical history
- There are other contraindications to the use of esketamine
Key Trial Info
Start Date :
February 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05229913
Start Date
February 20 2022
End Date
June 30 2023
Last Update
February 8 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.